BAFF在原发免疫性血小板减少症中的研究进展  

Research Progress of BAFF in Primary Immune Thrombocytopenia

作　　者：王蕾[1] 郭新红[2] 

机构地区：[1]新疆医科大学第一临床医学院,新疆 乌鲁木齐 [2]新疆医科大学第一附属医院血液三科,新疆 乌鲁木齐

出　　处：《临床医学进展》2023年第11期18522-18526,共5页Advances in Clinical Medicine

摘　　要：原发免疫性血小板减少症(ITP)是临床上常见的获得性自身免疫性疾病,尽管其发病机制尚未被完全阐明,但多认为B细胞、T细胞所致免疫失调是ITP发病的主要原因。随着研究的深入,一种对B细胞的生存、分化和免疫球蛋白产生起调节作用的细胞因子——B细胞激活因子(B-cell Activating Factor, BAFF),在系统性红斑狼疮、类风湿性关节炎、干燥综合征等多种自身免疫系统疾病中起着重要的作用,并与原发免疫性血小板减少症的发病密切相关。本文将对BAFF的最新功能研究、在免疫系统等疾病中的作用和机制,以及在ITP领域的最新研究进行全面综述,为进一步的研究和临床治疗提供理论依据。Primary immune thrombocytopenia (ITP) is a common acquired autoimmune disease in clinical practice. Although its pathogenesis has not been fully elucidated, it is widely believed that immune disorders caused by B and T cells are the main causes of ITP. With the deepening of research, a cy-tokine that regulates the survival, differentiation, and immunoglobulin production of B cells, B cell activating factor (BAFF), plays an important role in various autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome, and is closely related to the path-ogenesis of primary immune thrombocytopenia. This article will provide a comprehensive review of the latest functional research, roles and mechanisms of BAFF in diseases such as the immune sys-tem, as well as the latest research in the field of ITP, providing a theoretical basis for further re-search and clinical treatment.

关 键 词：B细胞激活因子 原发免疫性血小板减少症 研究进展 

分 类 号：R59[医药卫生—内科学]